Journal article
Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype
Clinical pharmacology and therapeutics, Vol.111(2), pp.366-372
02/2022
DOI: 10.1002/cpt.2309
PMCID: PMC8613315
PMID: 34032273
Abstract
Aminoglycosides are widely used antibiotics with notable side effects, such as nephrotoxicity, vestibulotoxicity, and sensorineural hearing loss (cochleotoxicity). MT-RNR1 is a gene that encodes the 12s rRNA subunit and is the mitochondrial homologue of the prokaryotic 16s rRNA. Some MT-RNR1 variants (i.e., m.1095T>C; m.1494C>T; m.1555A>G) more closely resemble the bacterial 16s rRNA subunit and result in increased risk of aminoglycoside-induced hearing loss. Use of aminoglycosides should be avoided in individuals with an MT-RNR1 variant associated with an increased risk of aminoglycoside-induced hearing loss unless the high risk of permanent hearing loss is outweighed by the severity of infection and safe or effective alternative therapies are not available. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of aminoglycosides based on MT-RNR1 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).
Details
- Title: Subtitle
- Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype
- Creators
- John Henry McDermott - University of ManchesterJoshua Wolf - St. Jude Children's Research HospitalKeito Hoshitsuki - University of PittsburghRachel Huddart - Stanford UniversityKelly E Caudle - St. Jude Children's Research HospitalMichelle Whirl-Carrillo - Stanford UniversityPeter S Steyger - Creighton UniversityRichard J H Smith - University of IowaNeal Cody - Mount Sinai HospitalCristina Rodriguez-Antona - Cancer GeneticsTeri E Klein - Stanford UniversityWilliam G Newman - University of Manchester
- Resource Type
- Journal article
- Publication Details
- Clinical pharmacology and therapeutics, Vol.111(2), pp.366-372
- DOI
- 10.1002/cpt.2309
- PMID
- 34032273
- PMCID
- PMC8613315
- ISSN
- 0009-9236
- eISSN
- 1532-6535
- Grant note
- PharmGKB R01 DC012049 / NIDCD NIH HHS R01 DC017955 / NIDCD NIH HHS R01 DC002842 / NIDCD NIH HHS American Foundation for Pharmaceutical Education Rho Chi Society R01 DC004555 / NIDCD NIH HHS R01 DC016680 / NIDCD NIH HHS U24 HG010135 / NHGRI NIH HHS U24 HG010615 / NHGRI NIH HHS TL1 TR001858 / NCATS NIH HHS IS-BRC-1215-20007 / NIHR BRC R56 DC004555 / NIDCD NIH HHS
- Language
- English
- Date published
- 02/2022
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Molecular Physiology and Biophysics; Anatomy and Cell Biology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Otolaryngology; Internal Medicine
- Record Identifier
- 9984256930402771
Metrics
16 Record Views